Pregnancy and primary pulmonary hypertension: Successful outcome with epoprostenol therapy

Rosalyn Stewart, Divina Tuazon, Gayle Olson, Alexander G. Duarte

Research output: Contribution to journalArticle

Abstract

Primary pulmonary hypertension (PPH) associated with pregnancy carries a high maternal mortality rate. Short-term epoprostenol infusion has been demonstrated to improve the hemodynamic profile in patients with PPH. We report a successful maternal-fetal outcome with epoprostenol therapy during pregnancy, cesarean section, and postpartum in a patient with PPH. Epoprostenol therapy did not produce any physical or developmental abnormalities in the fetus. A favorable maternal-fetal outcome may occur with a multidisciplinary approach.

Original languageEnglish (US)
Pages (from-to)973-975
Number of pages3
JournalChest
Volume119
Issue number3
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Epoprostenol
Pregnancy
Mothers
Maternal Mortality
Cesarean Section
Postpartum Period
Fetus
Therapeutics
Hemodynamics
Mortality
Familial Primary Pulmonary Hypertension

Keywords

  • Cesarean section
  • Epoprostenol
  • Pregnancy
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Pregnancy and primary pulmonary hypertension : Successful outcome with epoprostenol therapy. / Stewart, Rosalyn; Tuazon, Divina; Olson, Gayle; Duarte, Alexander G.

In: Chest, Vol. 119, No. 3, 01.01.2001, p. 973-975.

Research output: Contribution to journalArticle

Stewart, Rosalyn ; Tuazon, Divina ; Olson, Gayle ; Duarte, Alexander G. / Pregnancy and primary pulmonary hypertension : Successful outcome with epoprostenol therapy. In: Chest. 2001 ; Vol. 119, No. 3. pp. 973-975.
@article{a21e547e55a54564adb92269dd627f8b,
title = "Pregnancy and primary pulmonary hypertension: Successful outcome with epoprostenol therapy",
abstract = "Primary pulmonary hypertension (PPH) associated with pregnancy carries a high maternal mortality rate. Short-term epoprostenol infusion has been demonstrated to improve the hemodynamic profile in patients with PPH. We report a successful maternal-fetal outcome with epoprostenol therapy during pregnancy, cesarean section, and postpartum in a patient with PPH. Epoprostenol therapy did not produce any physical or developmental abnormalities in the fetus. A favorable maternal-fetal outcome may occur with a multidisciplinary approach.",
keywords = "Cesarean section, Epoprostenol, Pregnancy, Pulmonary hypertension",
author = "Rosalyn Stewart and Divina Tuazon and Gayle Olson and Duarte, {Alexander G.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1378/chest.119.3.973",
language = "English (US)",
volume = "119",
pages = "973--975",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - Pregnancy and primary pulmonary hypertension

T2 - Successful outcome with epoprostenol therapy

AU - Stewart, Rosalyn

AU - Tuazon, Divina

AU - Olson, Gayle

AU - Duarte, Alexander G.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Primary pulmonary hypertension (PPH) associated with pregnancy carries a high maternal mortality rate. Short-term epoprostenol infusion has been demonstrated to improve the hemodynamic profile in patients with PPH. We report a successful maternal-fetal outcome with epoprostenol therapy during pregnancy, cesarean section, and postpartum in a patient with PPH. Epoprostenol therapy did not produce any physical or developmental abnormalities in the fetus. A favorable maternal-fetal outcome may occur with a multidisciplinary approach.

AB - Primary pulmonary hypertension (PPH) associated with pregnancy carries a high maternal mortality rate. Short-term epoprostenol infusion has been demonstrated to improve the hemodynamic profile in patients with PPH. We report a successful maternal-fetal outcome with epoprostenol therapy during pregnancy, cesarean section, and postpartum in a patient with PPH. Epoprostenol therapy did not produce any physical or developmental abnormalities in the fetus. A favorable maternal-fetal outcome may occur with a multidisciplinary approach.

KW - Cesarean section

KW - Epoprostenol

KW - Pregnancy

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=0035092585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035092585&partnerID=8YFLogxK

U2 - 10.1378/chest.119.3.973

DO - 10.1378/chest.119.3.973

M3 - Article

C2 - 11243988

AN - SCOPUS:0035092585

VL - 119

SP - 973

EP - 975

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -